Floor Action:
The House and Senate are in session this week.
Banking- On Tuesday, the House is scheduled to consider H.R. 2543, the Financial Services Racial Equity, Inclusion, and Economic Justice Act, which includes provisions to collect data on and provide increased federal assistance for minority depository institutions (MDIs) owned by women.
Mark-Ups:
Appropriations- On Wednesday, the House Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration (FDA), and Related Agencies will consider the FY2023 Agriculture, Rural Development, FDA, and Related Agencies spending bill (as-yet-unnumbered). The spending bill includes funding for several domestic and international nutrition assistance programs and FDA user fees.
The House Appropriations Subcommittee on Defense will mark up the FY2023 Defense spending bill (as-yet-unnumbered). The measure contains funding for several programs, including the Defense Health Program and military personnel programs.
The House Appropriations Subcommittee on Legislative Branch will mark up the FY2023 Legislative Branch spending bill (as-yet-unnumbered), which is expected to include provisions related to funding for child care for congressional employees.
Also on Wednesday, the House Appropriations Subcommittee on Military Construction, Veterans’ Affairs (VA), and Related Agencies will consider the FY2023 Military Construction, VA, and Related Agencies spending bill (as-yet-unnumbered). The measure contains funding for military family housing and the Veterans Health Administration.
On Thursday, the House Appropriations Subcommittee on Financial Services will mark up the FY2023 Financial Service spending bill (as-yet-unnumbered). The measure includes funding provisions for the Small Business Administration, among other agencies.
Housing- On Tuesday, the House Financial Services Committee will mark up several bills, including H.R. 68, the Veterans, Women, Families with Children, Race, and Persons with Disabilities Housing Fairness Act of 2021, also known as the Housing Fairness Act of 2021.
Human Trafficking- On Wednesday, the House Judiciary Committee will mark up several bills, including H.R. 7181, the Human Trafficking Prevention Act.
Judiciary- On Wednesday, the House Judiciary Committee will mark up several bills, including H.R. 3285, the 21st Century President Act, which makes terms relating to the president and the spouse of a president gender neutral.
Military- On Tuesday, the Senate Armed Services Subcommittee on Personnel will mark up its portion of the FY2023 National Defense Authorization Act (NDAA). The measure contains provisions to address military sexual assault, among other provisions.
Also on Tuesday, the Senate Armed Services Subcommittee on Readiness and Management Support will consider its portion of the FY2023 NDAA, which includes provisions for military child development centers.
On Wednesday and Thursday, the Senate Armed Services Committee will mark up the proposed FY2023 NDAA.
Small Business- On Tuesday, the House Financial Services Committee will also mark up H.R. 7977, the Promoting Opportunities for Non-Traditional Capital Formation Act, which includes provisions related to capital raising options for women-owned small businesses.
Hearings:
Economy- On Wednesday, the House Committee on Ways and Means will hold a hearing, “The Burnout Epidemic and What Working Women Need for A Stronger Economy.”
Family Support- On Tuesday, the House Agriculture Committee will hold a hearing, “A 2022 Review of the Farm Bill: Stakeholder Perspectives on Non-Supplemental Nutrition Assistance Program (SNAP) USDA Nutrition Programs.”
On Wednesday, the Senate Finance Subcommittee on Competition Policy, Antitrust, and Consumer Rights will hold a hearing, “Baby Formula and Beyond: The Impact of Consolidation on Families and Consumers.”
Health- On Tuesday, the Senate Health, Education, Labor, and Pensions committee will consider, among other bills, S. 4348, the Food and Drug Administration (FDA) Safety and Landmark Advancements (FDASLA) Act. This bill includes provisions related to the FDA Office of Women’s Health and in vitro clinical tests and developers.